Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale Schenk

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Acta Neuropathologica Communications|January 15, 2017
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Early risk assessment for Alzheimer's diseaseMaria C Carrillo, Andrew Blackwell, Harald Hampel, et al.
Current Alzheimer Research|October 30, 2015
Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesMarcus Pickhardt, Thomas Neumann, Daniel Schwizer, et al.
Journal of Neuropathology and Experimental Neurology|November 7, 2006
Abeta species removal after abeta42 immunizationJames A R Nicoll, Edward Barton, Delphine Boche, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 2, 2013
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's diseaseKarl Herrup, Maria C Carrillo, Dale Schenk, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 11, 2014
Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like modelsDora Games, Elvira Valera, Brian Spencer, et al.
Neuro-Degenerative Diseases|January 10, 2008
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mousePeter Seubert, Robin Barbour, Karen Khan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 6, 2016
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis <sup>†</sup>Mark Renz, Ronald Torres, Philip J Dolan, et al.
Biochemistry|October 19, 2005
Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptidesChera Esh, Lyle Patton, Walter Kalback, et al.
Plos One|May 12, 2011
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseEliezer Masliah, Edward Rockenstein, Michael Mante, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Acta Neuropathologica Communications|January 15, 2017
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathyBrian Spencer, Elvira Valera, Edward Rockenstein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2009
Early risk assessment for Alzheimer's diseaseMaria C Carrillo, Andrew Blackwell, Harald Hampel, et al.
Current Alzheimer Research|October 30, 2015
Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesMarcus Pickhardt, Thomas Neumann, Daniel Schwizer, et al.
Journal of Neuropathology and Experimental Neurology|November 7, 2006
Abeta species removal after abeta42 immunizationJames A R Nicoll, Edward Barton, Delphine Boche, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 2, 2013
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's diseaseKarl Herrup, Maria C Carrillo, Dale Schenk, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 11, 2014
Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like modelsDora Games, Elvira Valera, Brian Spencer, et al.
Neuro-Degenerative Diseases|January 10, 2008
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mousePeter Seubert, Robin Barbour, Karen Khan, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 6, 2016
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis <sup>†</sup>Mark Renz, Ronald Torres, Philip J Dolan, et al.
Biochemistry|October 19, 2005
Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptidesChera Esh, Lyle Patton, Walter Kalback, et al.
Plos One|May 12, 2011
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseEliezer Masliah, Edward Rockenstein, Michael Mante, et al.
Pageof 7